Asymptomatic SARS-CoV-2 infection among healthcare workers in a non-COVID-19 teaching university hospital

Ahmed Mukhtar,1 Mostafa Alfishawy,2 Engy Alkhatib,3 Moushira Hosny,3 Mohamed Ollaek,1 Amal Elsayed,3 Marwa Rashad Salem,4 Doaa Ghaith3

1Department of Anesthesia, Faculty of Medicine, Cairo University, Cairo; 2Infectious Diseases Consultants and Academic Researchers of Egypt (IDCARE), Cairo; 3Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo; 4Department of Public Health and Community Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt

Abstract

Introduction: During the COVID-19 pandemic, most of the published reports on COVID-19 emphasized that health care workers (HCWs) get infected more than the general population representing one of the most vulnerable groups. However, that the real percentage of HCWs infected by SARS-CoV2 in Egypt remains unknown. The researchers conducted the current study to assess seroprevalence of SARS-CoV-2 IgG among HCWs working in a hospital with no SARS-CoV-2 patients, and to identify the potential factors associated with SARS-CoV2 IgG seropositivity.

Design and Methods: The current study is a cross-sectional study carried out among 455 HCWs at Cairo University Hospital. The researchers administered a questionnaire shortly before the SARS-CoV-2 rapid test is performed using closed-ended question format to obtain information on demographic data of the study participants including age, sex, specialty, clinical information including questions about medical conditions, and history of previous exposure with a confirmed or suspected case of COVID-19, and history of COVID-19- compatible symptoms during the previous 14 days (cough, sore throat, runny nose, fatigue, shortness of breath, fever, headache, vomiting, diarrhea, anosmia, ageusia, and chills).

Results: We screened 455 HCWs for SARS-CoV-2 antibodies, 31.4% were in the high-risk group, and 68.6% in the low-risk group. The overall IgG seroprevalence was, 36 (7.9%) (95% CI 5.8 to 10.8). The IgG seroprevalence was significantly higher in low-risk group 11% (35/312) versus high-risk group 0.7% (1/143, p<0.001.

Conclusion: Low seropositivity rates for SARS-CoV-2 among HCWs is suggestive of lack of immunity and we are still far from herd immunity.

Introduction

During Coronavirus Disease-2019 (COVID-19) pandemic, most of the published reports on COVID-19 emphasized that health care workers (HCWs) get infected more than the general population, representing one of the most vulnerable groups.1,2 According to Keeling et al.,3 HCWs represent 10% of overall cases and often more than 10% of any hospital’s personnel are commonly infected. Unlike Severe Acute Respiratory Syndrome (SARS) or the Middle East Respiratory Syndrome (MERS), COVID-19 has a lower mortality rate.2 Despite this lower mortality for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) the causative agent for COVID-19, its long incubation period resulted in a significant number of asymptomatic infected individuals.4 A study done at the University of Cambridge in a large United Kingdom teaching hospital revealed that 3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2.5 Another study conducted among HCWs at a clinic in Chile, revealed that a 3.4% of positivity in asymptomatic HCWs.6

Given that the real percentage of HCWs infected by SARS-CoV2 in Egypt remains unknown, and in response to the increased number of infected and deceased HCWs in Egypt, the researchers conducted the current study to assess the seroprevalence of SARS-CoV-2 IgG among HCWs working in a hospital with no SARS-CoV-2 patients, and to identify the potential factors associated with SARS-CoV-2 IgGs.

Design and Methods

Study design, setting, and population

The current study is a cross-sectional study carried out among HCWs at Cairo University Hospital. The researchers defined the study population as those HCWs who deliver care and services to

Significance for public health

The current study emphasizes that the low seropositivity rates for SARS-CoV-2 among health care workers is suggestive of lack of immunity and we are still far from herd immunity.
patients, including physicians and nurses. Inclusion criteria included being an adult (>18 years) working at Cairo University Hospital. Exclusion criteria included: a) absenteeism from the workplace in the last 30 days, retirement, or end-of-contract, and working in a COVID hospital.

From a total number of 700 HCs, 600 were eligible to take part in the study. We recruited 455, yielding a participation rate of 75%. All participants had worked at Cairo University Hospital for at least one month before study enrollment and were asymptomatic at the point of study recruitment. HCs who were previously diagnosed with COVID-19 were excluded from the study. We divide health care workers into high-risk and low-risk groups. High-risk HCs are defined as those who are dealing with aerosol generating procedure pulmonary and included three departments (anesthesia, critical care, and pulmonary care). Low risk HCs are those who are not involved in aerosol generating procedures.7

Procedures and data collection

Serum collection and self-administered questionnaire

Before serum collection, the researchers used an online short pre-screener questionnaire to determine the eligible HCs and exclude those with history of confirmed COVID-19 infection. It included the following questions: name, email address, mobile phone, specialty, the most suitable day for sample collection, and the history of confirmed COVID-19.

After that, the researchers administered a questionnaire shortly before the SARS-CoV-2 rapid test is performed using closed-ended question format to obtain information on:

a. Demographic data of the study participants including age, sex, specialty,

b. Clinical information including questions about medical conditions (chest diseases, cardiovascular diseases, diabetes, etc.), surgical history, medication intake such as (anticoagulant, immunosuppression, chemotherapy, steroids, antiepileptic, and vitamins), and smoking history,

c. History of previous exposure with a confirmed or suspected case of COVID-19, and history of COVID-19-compatible symptoms during the previous 14 days (cough, sore throat, runny nose, fatigue, shortness of breath, fever, headache, vomiting, diarrhea, anosmia, ageusia, and chills).

The questionnaire was based on Health workers exposure risk assessment and management in the context of COVID-19 virus.8

Detecting serum IgG against SARS-CoV-2

Samples were tested immediately by lateral flow immunoadsorbent (SD-Biosensor, Korea). The STANDARD Q COVID-19 IgM/IgG Duo Test showed according to the manufacturer’s insert, this test has a sensitivity 94% and specificity 95%. Validation of the results was done using iFlash-SARS-CoV-2 IgG chemiluminescent

| Table 1. Comparison between high risk and low risk health care workers regarding demographic, clinical information, exposure information, and COVID-19 like symptoms (n=455). |
|-------------------------------------------------|---------------|-------------------|---------------------|-------------------|
| Demographic characteristics                       | All subjects  | Health care workers | p                  |
| Age (mean ±SD)                                    | 32.8 ± 8.3    | 33.7 ± 8          | 32.4 ± 8.4         | 0.110             |
| Gender (n, %)                                     |               |                   |                    |
| Male                                             | 239 (52.5%)   | 92 (64.3%)        | 147 (47.1%)        | 0.001*            |
| Clinical history (n, %)                           |               |                   |                    |
| Past surgical history                             | 118 (25.9%)   | 59 (41.3%)        | 59 (18.9%)         | <0.001*           |
| Past medical history                              | 89 (19.6%)    | 30 (21%)          | 59 (18.9%)         | 0.606             |
| Hypertension                                      | 25 (5.5%)     | 11 (7.7%)         | 14 (4.5%)          | 0.164             |
| Diabetes                                          | 9 (2.0%)      | 2 (1.4%)          | 7 (2.2%)           | 0.726             |
| Asthma                                            | 19 (4.2%)     | 8 (5.6%)          | 11 (3.5%)          | 0.306             |
| Allergy                                           | 16 (3.5%)     | 5 (3.5%)          | 11 (3.5%)          | 0.988             |
| Other medical conditions #                        | 25 (5.5%)     | 10 (7.0%)         | 15 (4.8%)          | 0.342             |
| Medication intake                                 | 99 (21.8%)    | 32 (22.4%)        | 67 (21.5%)         | 0.628             |
| Smoking history (n, %)                            |               |                   |                    |
| Current smoker                                    | 24 (5.3%)     | 5 (3.5%)          | 19 (6.1%)          | 0.251             |
| Ex-smoker                                         | 62 (13.6%)    | 15 (10.5%)        | 47 (15.1%)         | 0.187             |
| Exposure information (n, %)                       |               |                   |                    |
| Direct contact with the environment where the confirmed COVID-19 was cared for | 187 (41.1%) | 74 (51.7%) | 113 (38.2%) | 0.002 * |
| History of travelling in proximity with confirmed COVID-19 patient | 100 (22%) | 14 (9.8%) | 36 (11.5%) | 0.580 |
| Family member with COVID-19 diagnosis             | 24 (5.3%)     | 6 (4.2%)          | 18 (5.8%)          | 0.486             |
| Family member with pneumonia diagnosis            | 11 (2.4%)     | 4 (2.8%)          | 7 (2.2%)           | 0.747             |
| Symptoms compatible with COVID-19 in the past 2 weeks (n, %) |     |                   |                    |
| Flu-like illness                                   | 108 (23.7%)   | 50 (35%)          | 58 (18.6%)         | <0.001*           |
| Wheezing                                          | 42 (9.2%)     | 15 (10.5%)        | 27 (8.7%)          | 0.530             |
| Fever                                             | 61 (13.4%)    | 25 (17.5%)        | 36 (11.5%)         | 0.084             |
| Gastroenteritis                                   | 96 (21.1%)    | 34 (23.8%)        | 62 (19.9%)         | 0.343             |
| Sore throat                                       | 133 (29.2%)   | 61 (42.7%)        | 72 (23.1%)         | <0.001*           |
| Muscle aches                                      | 81 (17.8%)    | 34 (24.5%)        | 47 (15.1%)         | 0.024 *           |
| IgG seroprevalence                                |               |                   |                    |
| +VE                                               | 36 (7.9%)     | 1 (0.7)           | 35 (11.2)          | <0.001*           |

1Liver disease, renal disease, cancers and autoimmune and other immunological disorders; *statistically significant.
immunoassay kit (LOT 20200307; REF C86095G; YHLO Biotech, Shenzhen). Per manufacturers’ instructions, the sensitivity and specificity of the kits were 90% and 95% respectively for IgG. In this assay the nucleocapsid (N) protein was combined with the spike (S) glycoprotein antigens to increase the sensitivity. The levels of IgG antibodies were positively correlated with the relative luminescence unit (RLU) and were evaluated as arbitrary units per milliliter (AU/mL).

The study researchers via short message informed participants who tested positive for SARS-CoV-2 antibodies.

Statistical analysis

The researchers used the Statistical Package of Social Science Software program (IBM SPSS Statistics for Windows, Ver. 25.0; IBM Corp., Armonk, NY, USA). We summarized the data using range, mean, and standard deviation for quantitative variables and frequency and percentage for qualitative ones. We performed the comparison between groups for qualitative variables using Chi-square or Fisher’s exact tests, while for quantitative variables we conducted the comparison using Independent t-test; p-values less than 0.05 were considered statistically significant.

Results

Between 20/5/2020 and 11/6/2020, we screened a total number of 455 HCWs for the SARS-CoV-2 IgG antibody. Among them, 143 (31.4%) were in the high-risk group and 312 (68.6%) in the low-risk group. We present the demographic characteristics of the two groups in Table 1. Out of 455 HCWs, 36 tested positive by both IgG rapid test and chemiluminescent immunoassay; this corresponds to an overall seroprevalence estimate of 7.9% (95% CI 5.8 to 10.8). The prevalence of IgG against SARS-CoV2 among the high-risk group was 1 (0.7%), in contrast, the seroprevalence was significantly higher in the low-risk group 11% (35/312) p<0.001. Direct contact with an environment where the confirmed COVID-19 cared, was significantly higher in the high risk compared to the low-risk group odds ratio (95% confidence interval) OR [95% CI]: 1.9 [1.3-2.8], p<0.0001.

The researchers also compared the subjects’ characteristics between those with anti-SARS-CoV-2 IgG positive and negative. Demographic data, clinical information, and smoking history were comparable between both groups Regarding symptoms compatible with COVID-19 in the past two weeks, 141(31%) did not report any COVID-19 like symptoms. One third (29%) reported having a sore throat, followed by Flu-like illness 104 (23%), and muscle aches 82 (18%). However, there was no significant difference between study participants who tested positive and those who were tested negative (Table 2).

Discussion

The main outcome of the present study that the overall seroprevalence among HCWs is low; 7.9%. Moreover, IgG seropositivity was less prevalent among the high-risk group compared to the low-risk group. In the current study, the seroprevalence among HCWs was 7.9%. Consistent with the current study finding, several studies found that the seroprevalence among healthcare workers was low and varied from 0% to 8.6%.\(^9,10\)

We conducted the present study in a large non-COVID-19 university teaching hospital aiming at predicting the real prevalence of asymptomatic COVID-19 disease among the general population. Interestingly, the author supposed at the start of research that the seroprevalence would be high among HCWs. However, the low prevalence rate among HCWs (7.9%) may suggest lower rates among the general population. Several recent larger-scale studies

Table 2. Association between demographic characteristics, clinical history, exposure information and COVID-19 IgG seroprevalence (n=455).

| Demographic characteristics | +VE n=36 | -VE n=419 | p   |
|-----------------------------|----------|-----------|-----|
| Age (mean ± SD)             | 33.4 ± 9.3 | 32.8 ± 8.2 | 0.707 |
| Gender (n, %)               |          |           |     |
| Male                        | 16 (44.4%) | 223 (53.2%) | 0.312 |
| Clinical history (n, %)     |          |           |     |
| Past surgical history (n, %)| 12 (33.3%) | 106 (25.3%) | 0.291 |
| Past medical history (n, %) | 8 (22.2%)  | 81 (19.3%)  | 0.675 |
| Hypertension                | 2 (5.6%)  | 23 (5.5%)  | 1.000 |
| Diabetes                    | 0 (0%)    | 9 (2.1%)   | 1.000 |
| Asthma                      | 1 (2.8%)  | 18 (4.3%)  | 1.000 |
| Allergy                     | 1 (2.8%)  | 15 (3.6%)  | 1.000 |
| Other medical conditions\(^4\) | 3 (8.3%)  | 22 (5.3%)  | 0.436 |
| Medication intake (n, %)    | 9 (25%)   | 90 (21.5%) | 0.623 |
| Smoking history (n, %)      |          |           |     |
| Current smoker              | 2 (5.6%)  | 22 (5.3%)  | 1.000 |
| Ex-smoker                   | 6 (16.7%) | 56 (13.4%) | 0.611 |
| Non-smoker                  | 28 (77.8%)| 341 (81.4%)| 0.596 |
| Symptoms in the past 2 weeks (n, %) | | | |
| Flu-like illness            | 8 (22.2%) | 100 (23.9%) | 0.834 |
| Wheezing                    | 6 (16.7%) | 36 (8.6%)  | 0.127 |
| Fever                       | 5 (13.9%) | 56 (13.4%) | 1.000 |
| Gastroenteritis             | 8 (22.2%) | 88 (21%)   | 0.863 |
| Sore throat                 | 9 (25%)   | 124 (29.6%)| 0.561 |
| Muscle aches                | 10 (27.8%)| 71 (16.9%) | 0.103 |

\(^4\)Liver disease, renal disease, cancers, and autoimmune and other immunological disorders.
documented low prevalence among the general population. The Spanish study, which included over 60,000 participants, showed a nationwide seroprevalence of 5.0% (population-based seroepidemiological study).11 We got similar numbers across the 2766 participants in the Swiss study, with seroprevalence data from Geneva reaching 10.8%.12 All these findings from the current study and others documented that most of the population appears to have remained unexposed to SARS-CoV-2, even in areas with widespread virus circulation.

The second main finding was that the IgG seropositivity was more prevalent among low-risk HCWs than high risk HCW. Inconsistent with the present study finding, a recent study conducted in Germany found that the seroprevalence was low in the high-risk HCWs (1.2%) versus the low-risk group (5.2%).12 Out of 42,600 HCWs caring for COVID-19 patients in the second half of the China epidemic, none was infected, suggesting that sufficient precautions and rigorous enforcement of PPE are the major determinants for eliminating COVID-19 infection,9 and consistent with data suggesting that HCWs in hospitals involved in COVID-19 care could have a lower burden of infection than those not taking part in COVID-19 care.13 Contradicting results are noted in a large study from Madrid where the SARS-CoV-2 prevalence is higher in HCW working in areas with exposure to COVID-19 (34%) compared with the low-risk area (26%) and external workers (30%) in Madrid,13 and to a recent study conducted among frontline HCWs during the peak of COVID-19 pandemic in a tertiary care hospital in Egypt with higher prevalence (14.3%).14 The possible explanation of the current study finding was that the high-risk group had a high perception of increased risk of SARS-CoV-2 transmission leading to more careful practices and more use of PPE thus, a lower risk of acquiring the infection.14

The current study findings should be viewed with respect to the following limitations: First, this study was limited to one hospital, so its findings may not be generalizable to HCWs in other workplaces, however, the current study was conducted to explore the situation in this new area of inquiry. Second, detection of SARS-CoV-2 IgG antibody in a single sample may miss any SARS-CoV-2 infected HCW yet to seroconvert, although this is likely to be minimal.

In conclusion, the IgG seroprevalence among the enrolled HCWs of a tertiary non-COVID hospital in Egypt was 7.9%. The low seropositivity against SARS-CoV-2 among HCWs who have not been exposed to COVID-19 patients suggests that we are far behind from herd immunity.

References
1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
2. Mahase E. Coronavirus COVID-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ 2020;368:m641.
3. Keeling MJ, Hollingsworth TD, Read JM. Efficacy of contact
tracing for the containment of the 2019 novel coronavirus (COVID-19) J Epidemiol Community Health 2020;74:861-6.
4. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177-9.
5. Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife 2020;9:e58728.
6. Olmos C, Campaña G, Monreal V, et al. SARS-CoV-2 infection in asymptomatic healthcare workers at a clinic in Chile. PLoS One 2021;16:e0245913.
7. Occupational Safety and Health Administration, United States Department of Health. COVID-19 and the workplace. Accessed: 2021 Mar 3. Available from: www.osha.gov/publications
8. World Health Organization. Health workers exposure risk assessment and management in the context of COVID-19 virus: interim guidance, 4 March 2020. World Health Organization. Available from: https://apps.who.int/iris/handle/10665/331340
9. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. BMJ 2020;369:m2195.
10. Paderno A, Fior M, Berretti G, et al. SARS-CoV-2 infection in healthcare workers: cross-sectional analysis of an otolaryngology unit. Otolaryngol Head Neck Surg 2020;163:671-2.
11. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:535-44.
12. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 2020;396:313-9.
13. Korth J, Wilde B, Dolff S, Anastasiou, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol 2020;128:104437.
14. Galan I, Velasco M, Casas ML, et al. SARS-CoV-2 seroprevalence among all workers in a teaching hospital in Spain: Unmasking the 267 risk. medRxiv 2020.05.29.20116731.
15. Abdelmoniem R, Fouad R, Shawky S, et al. SARS-CoV-2 infection among asymptomatic healthcare workers of the emergency department in a tertiary care facility. J Clin Virol 2021;134:104710.